Founded in 2015 to advance epigenetic approaches to cancer, EpiAxis has re-energised under new leadership in 2024. Building on advances in peptide chemistry and LSD1 biology, we are driving a pipeline of differentiated inhibitors supported by strong IP, academic collaborations, and investor commitment.
We are now raising US$500k (Nov 2025) to select our lead candidate and indication by Q2 2026. A planned institutional raise (~US$5m) will fund toxicology, CMC development, and a Phase I healthy volunteer study. Our goal is to deliver a clinically derisked asset by mid-2026 and create a clear path to a US$100m+ value inflection by 2028.
At EpiAxis, our mission is to change the course of advanced cancers by targeting the epigenetic regulator LSD1. We are developing next-generation therapies designed to overcome resistance, extend treatment possibilities, and bring new hope to patients facing aggressive solid tumours.
Through a relentless focus on high-quality translational science, strategic collaborations, and a clear clinical pathway, we aim to deliver breakthrough medicines that improve outcomes for patients and create lasting value for our partners and shareholders.
EpiAxis is led by CEO Dr. Ben Buckley, supported by Chair Charles Lindop and directors Rob McInnes and Phil Williamson. Dr. David Fuller serves as Chief Medical Officer, bringing clinical experience in oncology and translational research.
An experienced drug discovery scientist with over a decade in small molecule development, project management, and technology transfer, passionate about advancing innovative therapies.
CEO
A biopharma leader with 35+ years of global experience in oncology and haematology drug development, commercialization, and board leadership, credited with multiple product approvals and INDs worldwide.
Chief Medical Officer
Charles is a seasoned tech industry advisor, investor, and non-executive director with deep experience in M&A, IPOs, and corporate growth across the cyber, cloud, and technology sectors.
Chair
Rob McInnes is a leading Australian IP licensing lawyer and advisor, recognized globally for his expertise in structuring technology commercialization deals and guiding founders, investors, and research organizations.
Director
Founder of Intelledox (acquired by AKKR/Smart Communications), now mentoring, investing, and supporting purpose-driven high-growth companies.
Director
An experienced scientific advisor and board director with deep expertise in drug discovery, research strategy, and mentoring, supporting both early-stage ventures and non-profit causes.
Pharmacology and oncology
Dr. Pamela Munster is a UCSF professor, oncologist, researcher, and founder of Alessa Therapeutics, dedicated to advancing novel cancer therapies and breast cancer awareness worldwide.
Early-phase clinical trials
Tomi is Chief Drug Hunter and President of Maestro Therapeutics, a veteran biotech leader with four decades of experience and credited with bringing multiple breakthrough peptide and small-molecule drugs to market.
Peptide chemistry
We also collaborate with leading institutions including the University of Canberra, the Australian National University, UMass Boston, the University of Manitoba, and PeterMacCallum Cancer Centre, strengthening our global research network.
Dr. Joel Pearson is a cancer biologist and professor whose research uncovers fundamental principles of cancer biology to develop novel therapies, with a focus on aggressive neural and neuroendocrine cancers.
Small Cell Lung Cancer
Professor Rob is a gastrointestinal cancer researcher and academic leader with over 200 publications, decades of NHMRC funding, and a legacy of mentoring 35 PhD graduates.
Colorectal cancer
A prostate cancer researcher focused on androgen receptor biology, therapy resistance, and novel molecular mechanisms driving disease progression and treatment response.
Prostate cancer